VOOPOO
20.4.2022 06:10:47 CEST | Business Wire | Press release
VOOPOO, leading vape brand, along with its sister brand ZOVOO, is looking forward to meeting you at the National Convenience Show Birmingham 2022 on April 25-27.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220414005472/en/
The National Convenience Show Birmingham is not only the largest retail show in the UK, but also the most professional world-class event in the world’s retail industry. This year, the event will gather 1,000+ global vendors to share cutting-edge consumer insights and commercial trends, and discuss hot topics such as technology, sustainable development, food hygiene and health, and social media. 90,000+ professional visitors are expected to visit the event.
As the leader of vape technology, VOOPOO and ZOVOO will feature three new products of the year in a 25sqm uniquely-designed booth and showcase new technological breakthroughs and smarter experience in the vape industry. On this occasion, VOOPOO looks forward to establishing connections with more excellent partners, peer brands and users, to jointly develop the market.
ARGUS GT 2, a member of VOOPOO’s high-end ARGUS series and the first MOD product in 2022, will be exhibited at the event. While inheriting the classic style of ARGUS GT, ARGUS GT 2 also provides a fully upgraded professional vape experience, a masculine aesthetic design and an improved collision-proof performance to satisfy massive clouds lovers and those vapers who pursue intensive explosion, high performance and high durability. It is poised to define a new height of user experience.
Powerful TPP vape platform, high power and massive clouds
ARGUS GT 2 is compatible with VOOPOO’s universal TPP vape platform, and with a maximum output power of 200W. The moment the ignition button is pressed, massive clouds will volcanically spew out, bringing users the ultimate enjoyment of taste and the strongest visual pleasure. In addition, with a 200W stable output, users are allowed to enjoy the luxurious experience in a leisurely manner.
Top water, dust and collision-proof body to withstand extreme outdoor scenarios
ARGUS GT 2 has obtained the IP68 rating, the highest rating of protection against water, dust and collision. After thousands of tests, the team for ARGUS GT 2 has created a powerful double-layer waterproof, dust-proof, frost-proof, and collision-proof body that can withstand various extreme outdoor environments like temperatures ranging from minus 20°C to 60°C without affecting its performance. Such a hard and durable ARGUS GT 2 will definitely become the best choice for outdoor vapers.
Innovative volcano crater design to guarantee both massive clouds and leak-proofness
Featured with massive clouds, ARGUS GT 2 comes with the MAAT TANK NEW, which has the unique two-way volcano crater airflow design that can increase the airflow rate by 60% and produce thicker clouds at a higher speed; at the same time, it can better drain the condensed liquid to the isolation section at the bottom, so as to create the ultimate leak-proof experience.
Top GENE.TT 2.0 chip to enable new experience of all-scenario intelligence
ARGUS GT 2 features GENE.TT 2.0 technology and is equipped with an upgraded smart chipset which can automatically match power, and supports multi-mode switching between Smart, RBA, Turbo and TC, allowing vapers to easily control their daily experience. In addition, it adopts a hidden 3A TYPE-C fast charging design, and the charging speed is also improved by 30%. VOOPOO products are rich in color and unique in design. ARGUS GT 2 to be displayed this time is no exception. It will offer five new colors including carbon fiber grey, lime green, and dark blue. This perfect fusion of technology and design will surely bring another surprise to the industry.
As a disruptor in the POD market, ZOVOO will bring DRAGBAR 600s, the first disposable vape with a light bar. The DRAGBAR series have been loved by global users since their launch. The innovative use of ethyl maltol to provide the sweetness in e-liquid can effectively avoid sugar addiction which causes harm to the human body, and are popular among vapers who favor sugar-free and low-sugar e-liquid. What kind of disruptive technology will the DRAGBAR 600s present at the show? In addition to ARGUS GT 2, what new surprises will VOOPOO's other two mysterious new products bring to the industry? Let's wait and see at Booth E20 of National Convenience Show Birmingham 2022 from April 25 to 27!
About VOOPOO
Founded in 2017, VOOPOO has rapidly grown and recognized by vapers from around the world with its DRAG series. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operation. It has four flagship product series: DRAG, VINCI, ARGUS and V Series, altogether providing consumers with a safe, reliable and diverse all-scenario product ecosystem. Currently, VOOPOO products are sold in more than 70 countries and regions in North America, Europe and Asia. VOOPOO will pursue long-term value and strengthen exchanges and cooperation in technology, brand, and supply chain, and promote the innovation and development of the vape industry. For more information, please visit https://www.voopoo.com/ and follow our Instagram, Facebook and TikTok.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220414005472/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom